Penumbra Toekomstige groei
Future criteriumcontroles 4/6
Penumbra zal naar verwachting groeien in winst en omzet met respectievelijk 42.4% en 12.4% per jaar. De winst per aandeel zal naar verwachting groeien met 42.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.9% zijn.
Belangrijke informatie
42.4%
Groei van de winst
42.7%
Groei van de winst per aandeel
Medical Equipment winstgroei | 17.4% |
Inkomstengroei | 12.4% |
Toekomstig rendement op eigen vermogen | 11.9% |
Dekking van analisten | Good |
Laatst bijgewerkt | 31 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Penumbra (NYSE:PEN) May Have Issues Allocating Its Capital
Oct 06Penumbra Grinding Through A Painful Growth Expectations Reset
Aug 20What You Can Learn From Penumbra, Inc.'s (NYSE:PEN) P/S
Aug 01Penumbra, Inc. (NYSE:PEN) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jul 11Returns At Penumbra (NYSE:PEN) Appear To Be Weighed Down
Jun 19Penumbra: Appeal Improves As Operating Leverage Continues
May 30Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors
Apr 12Estimating The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Mar 21Some Investors May Be Worried About Penumbra's (NYSE:PEN) Returns On Capital
Jan 23A Look At The Fair Value Of Penumbra, Inc. (NYSE:PEN)
Nov 16Penumbra: Appeal Improves, Just Not Appealing Yet
Oct 16Returns On Capital Signal Tricky Times Ahead For Penumbra (NYSE:PEN)
Oct 05Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy
Sep 01A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Aug 15Penumbra (NYSE:PEN) Has Some Way To Go To Become A Multi-Bagger
Jun 28Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors
Jun 22Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult
Jun 02We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn
Apr 01Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M
Feb 23Penumbra Riding Higher On Upcoming Launches And Rerating
Jan 12Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy
Nov 03Penumbra cut to Neutral at Citi on macro concerns
Oct 05Penumbra, Asahi team up to bring blood clot removing device Indigo to Japan
Sep 22Penumbra stock rises ~11% after announcing European launch of catheters for stroke care
Sep 07Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 1,553 | 192 | 141 | 154 | 13 |
12/31/2025 | 1,360 | 145 | 169 | 114 | 16 |
12/31/2024 | 1,190 | 22 | 141 | 40 | 16 |
9/30/2024 | 1,164 | 35 | 133 | 154 | N/A |
6/30/2024 | 1,134 | 14 | 110 | 128 | N/A |
3/31/2024 | 1,096 | 93 | 104 | 122 | N/A |
12/31/2023 | 1,059 | 91 | 81 | 97 | N/A |
9/30/2023 | 995 | 41 | 47 | 62 | N/A |
6/30/2023 | 938 | 29 | 1 | 19 | N/A |
3/31/2023 | 885 | 6 | -56 | -38 | N/A |
12/31/2022 | 847 | -2 | -75 | -56 | N/A |
9/30/2022 | 830 | -31 | -90 | -66 | N/A |
6/30/2022 | 806 | -19 | -40 | -17 | N/A |
3/31/2022 | 782 | -6 | -3 | 19 | N/A |
12/31/2021 | 748 | 5 | -12 | 10 | N/A |
9/30/2021 | 710 | 34 | 0 | 17 | N/A |
6/30/2021 | 671 | 16 | -39 | -23 | N/A |
3/31/2021 | 592 | -5 | -60 | -42 | N/A |
12/31/2020 | 560 | -16 | -58 | -33 | N/A |
9/30/2020 | 539 | -10 | -55 | -26 | N/A |
6/30/2020 | 527 | 11 | -34 | -1 | N/A |
3/31/2020 | 556 | 39 | -7 | 23 | N/A |
12/31/2019 | 547 | 48 | 5 | 27 | N/A |
9/30/2019 | 523 | 45 | 32 | 29 | N/A |
6/30/2019 | 495 | 15 | 7 | 18 | N/A |
3/31/2019 | 471 | 12 | 7 | 16 | N/A |
12/31/2018 | 445 | 7 | 19 | 29 | N/A |
9/30/2018 | 420 | 9 | -12 | 20 | N/A |
6/30/2018 | 392 | 28 | N/A | 21 | N/A |
3/31/2018 | 363 | 13 | N/A | 21 | N/A |
12/31/2017 | 334 | 5 | N/A | 13 | N/A |
9/30/2017 | 311 | -7 | N/A | 3 | N/A |
6/30/2017 | 294 | 5 | N/A | -2 | N/A |
3/31/2017 | 279 | 9 | N/A | -9 | N/A |
12/31/2016 | 263 | 15 | N/A | -13 | N/A |
9/30/2016 | 245 | 18 | N/A | -11 | N/A |
6/30/2016 | 228 | 6 | N/A | -21 | N/A |
3/31/2016 | 205 | 3 | N/A | -20 | N/A |
12/31/2015 | 186 | 1 | N/A | -21 | N/A |
9/30/2015 | 167 | 0 | N/A | -18 | N/A |
6/30/2015 | 149 | -1 | N/A | -17 | N/A |
3/31/2015 | 138 | -1 | N/A | -9 | N/A |
12/31/2014 | 126 | -1 | N/A | -6 | N/A |
12/31/2013 | 89 | 1 | N/A | -3 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei PEN ( 42.4% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van PEN ( 42.4% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).
Hoge groeiwinsten: De winst van PEN zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van PEN ( 12.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van PEN ( 12.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen PEN zal naar verwachting over 3 jaar laag zijn ( 11.9 %).